Anne Hamilton

20.2k total citations · 1 hit paper
72 papers, 3.1k citations indexed

About

Anne Hamilton is a scholar working on Oncology, Molecular Biology and Reproductive Medicine. According to data from OpenAlex, Anne Hamilton has authored 72 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Oncology, 24 papers in Molecular Biology and 14 papers in Reproductive Medicine. Recurrent topics in Anne Hamilton's work include Cancer Treatment and Pharmacology (20 papers), Ovarian cancer diagnosis and treatment (14 papers) and Melanoma and MAPK Pathways (9 papers). Anne Hamilton is often cited by papers focused on Cancer Treatment and Pharmacology (20 papers), Ovarian cancer diagnosis and treatment (14 papers) and Melanoma and MAPK Pathways (9 papers). Anne Hamilton collaborates with scholars based in Australia, United States and United Kingdom. Anne Hamilton's co-authors include Richard Kefford, Alexander M. Menzies, Richard A. Scolyer, Lauren E. Haydu, Georgina V. Long, John F. Thompson, Adnan Nagrial, Michael Hughes, Graham J. Mann and Martine Piccart and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Anne Hamilton

71 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma

2011 794 citations Anne Hamilton et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anne Hamilton Australia	29	1.9k	1.4k	569	450	412	72	3.1k
Trivadi S. Ganesan India	32	1.2k 0.7×	1.7k 1.2×	590 1.0×	365 0.8×	254 0.6×	166	3.8k
Timothy R. Wilson United States	32	2.2k 1.1×	2.3k 1.7×	961 1.7×	1.1k 2.5×	296 0.7×	88	4.3k
José Alejandro Pérez Fidalgo Spain	27	1.4k 0.8×	1.3k 0.9×	853 1.5×	569 1.3×	265 0.6×	136	2.9k
Nikhil Wagle United States	27	1.9k 1.0×	2.6k 1.9×	1.3k 2.3×	1.1k 2.3×	496 1.2×	102	4.7k
Paul Frankel United States	34	1.9k 1.0×	1.8k 1.3×	658 1.2×	967 2.1×	196 0.5×	214	4.1k
Jeremy Braybrooke United Kingdom	23	1.4k 0.7×	1.0k 0.7×	979 1.7×	674 1.5×	383 0.9×	64	2.9k
Sun‐Young Kong South Korea	32	1.3k 0.7×	1.4k 1.0×	683 1.2×	498 1.1×	310 0.8×	204	3.7k
Francesco Caponigro Italy	28	2.3k 1.2×	2.0k 1.5×	552 1.0×	1.2k 2.8×	112 0.3×	101	4.6k
Maryse Fiche France	29	1.6k 0.9×	1.2k 0.9×	976 1.7×	711 1.6×	553 1.3×	83	3.4k
Akira Hirasawa Japan	34	738 0.4×	1.4k 1.0×	790 1.4×	252 0.6×	323 0.8×	130	3.0k

Countries citing papers authored by Anne Hamilton

Since Specialization

Citations

This map shows the geographic impact of Anne Hamilton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anne Hamilton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anne Hamilton more than expected).

Fields of papers citing papers by Anne Hamilton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anne Hamilton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anne Hamilton. The network helps show where Anne Hamilton may publish in the future.

Co-authorship network of co-authors of Anne Hamilton

This figure shows the co-authorship network connecting the top 25 collaborators of Anne Hamilton. A scholar is included among the top collaborators of Anne Hamilton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anne Hamilton. Anne Hamilton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kostos, Louise, Jayesh Desai, Lisa Orme, et al.. (2024). Oral Etoposide for Relapsed or Refractory Ewing Sarcoma in Adolescent and Adult Patients. Sarcoma. 2024(1). 8247342–8247342. 1 indexed citations

Bressel, Mathias, Yi-An Ko, Anne Hamilton, et al.. (2024). Beacon: A phase II study of bevacizumab, atezolizumab, and cobimetinib in patients with recurrent, platinum resistant, high grade serous ovarian cancer.. Journal of Clinical Oncology. 42(16_suppl). 5565–5565. 1 indexed citations

Lewin, Jeremy, Jayesh Desai, Lisa Orme, et al.. (2024). Clinical Impact of Comprehensive Molecular Profiling in Adolescents and Young Adults with Sarcoma. Journal of Personalized Medicine. 14(2). 128–128. 2 indexed citations

Blagden, Sarah P., Anne Hamilton, Linda Mileshkin, et al.. (2018). Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer. Clinical Cancer Research. 25(5). 1472–1478. 50 indexed citations

Ho, Gwo‐Yaw, Holly E. Barker, Cassandra J. Vandenberg, et al.. (2018). SRA737, a novel Chk1 inhibitor, shows efficacy in CCNE1-amplified and MYCN-overexpressing high-grade serous ovarian cancer patient-derived xenograft models. European Journal of Cancer. 103. 1 indexed citations

Kentwell, Maira, Yoland Antill, C. David Wrede, et al.. (2017). Mainstreaming cancer genetics: A model integrating germline BRCA testing into routine ovarian cancer clinics. Gynecologic Oncology. 145(1). 130–136. 80 indexed citations

Leitão, Mario M., Xi Cheng, Anne Hamilton, et al.. (2014). Gynecologic Cancer InterGroup (GCIG) Consensus Review for Vulvovaginal Melanomas. International Journal of Gynecological Cancer. 24(9 Suppl 3). S117–S122. 59 indexed citations

Vardy, Janette L., Haryana M. Dhillon, Stephen Clarke, et al.. (2013). Investigation of herb-drug interactions with ginkgo biloba in women receiving hormonal treatment for early breast cancer. SpringerPlus. 2(1). 126–126. 14 indexed citations

Remick, Scot C., Chris H. Takimoto, Ramesh K. Ramanathan, et al.. (2011). Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. Cancer Chemotherapy and Pharmacology. 68(6). 1439–1447. 35 indexed citations

10.

Zardawi, Ibrahim M., Catriona M. McNeil, Ewan K.A. Millar, et al.. (2010). High Notch1 protein expression is an early event in breast cancer development and is associated with the HER‐2 molecular subtype. Histopathology. 56(3). 286–296. 48 indexed citations

11.

Sharma, Rohini, Jane Beith, & Anne Hamilton. (2005). Systematic review of LHRH agonists for the adjuvant treatment of early breast cancer. The Breast. 14(3). 181–191. 11 indexed citations

12.

Paridaens, Robert, Luc Dirix, Caroline Lohrisch, et al.. (2003). Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Annals of Oncology. 14(9). 1391–1398. 172 indexed citations

13.

Haigentz, Missak, Mimi Kim, Joan Sorich, et al.. (2003). Phase I study of amifostine as a cytoprotector of the gemcitabine/cisplatin combination in patients with advanced solid malignancies. Anti-Cancer Drugs. 14(4). 321–326. 4 indexed citations

14.

Sewak, Sanjeev, Abraham Chachoua, Anne Hamilton, et al.. (2003). A phase I study of paclitaxel, estramustine phosphate and vinorelbine (Pacl-E-Vin) in advanced malignancies: triple tubulin targeting. Anti-Cancer Drugs. 14(1). 67–72. 6 indexed citations

15.

Muggia, Franco M., Leonard Liebes, Maitreyee Hazarika, et al.. (2002). Phase I and pharmacologic study of i.p. 9-aminocamptothecin given as six fractions over 14 days. Anti-Cancer Drugs. 13(8). 819–825. 9 indexed citations

16.

Hamilton, Anne, Laura Biganzoli, Robert E. Coleman, et al.. (2002). EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx®, Doxil®) at a 6-week interval in patients with metastatic breast cancer. Annals of Oncology. 13(6). 910–918. 83 indexed citations

17.

Awada, Ahmad, Laura Biganzoli, Tanja Čufer, et al.. (2002). An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes. European Journal of Cancer. 38(6). 773–778. 6 indexed citations

18.

Bonnefoi, Hervé, Laura Biganzoli, Tanja Čufer, et al.. (2001). An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer. Breast Cancer Research and Treatment. 70(1). 55–63. 5 indexed citations

19.

Hamilton, Anne, J.A. Roy, L.V.A.M. Beex, et al.. (2000). EORTC 10941: A phase II study of liarozole in postmenopausal patients with ‘Chemotherapy-Resistant’ or ‘Potentially Hormone Sensitive’ metastatic breast cancer. Breast Cancer Research and Treatment. 60(2). 181–188. 3 indexed citations

20.

Muggia, Franco M., Leonard Liebes, M Potmĕsil, et al.. (2000). Intraperitoneal Topoisomerase‐I Inhibitors: Preliminary Findings with 9‐Aminocamptothecin. Annals of the New York Academy of Sciences. 922(1). 178–187. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact